These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 28458618)

  • 1. A Review on Platelet Activating Factor Inhibitors: Could a New Class of Potent Metal-Based Anti-Inflammatory Drugs Induce Anticancer Properties?
    Papakonstantinou VD; Lagopati N; Tsilibary EC; Demopoulos CA; Philippopoulos AI
    Bioinorg Chem Appl; 2017; 2017():6947034. PubMed ID: 28458618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro effects of vitamin supplements on platelet-activating factor and its metabolism in age-related macular degeneration.
    Moschos MM; Chatziralli IP; Stamatakis G; Papakonstantinou VD; Demopoulos CA
    Cutan Ocul Toxicol; 2014 Sep; 33(3):235-41. PubMed ID: 24147947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet-activating factor synthesis by peritoneal mast cells and its inhibition by two quinoline-based compounds.
    Hogaboam CM; Donigi-Gale D; Shoupe TS; Bissonnette EY; Befus AD; Wallace JL
    Br J Pharmacol; 1992 Jan; 105(1):87-92. PubMed ID: 1596692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Vitro Effects of Anti-Glaucomatous Eye Drops on Platelet-Activating Factor and its Metabolism.
    Moschos MM; Chatziralli IP; Stamatakis G; Papakonstantinou VD; Tsatsos M; Demopoulos CA
    Semin Ophthalmol; 2017; 32(2):198-203. PubMed ID: 26270771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?
    Tsoupras AB; Chini M; Tsogas N; Fragopoulou E; Nomikos T; Lioni A; Mangafas N; Demopoulos CA; Antonopoulou S; Lazanas MC
    AIDS Res Hum Retroviruses; 2008 Aug; 24(8):1079-86. PubMed ID: 18620493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
    Salari H; Dryden P; Howard S; Bittman R
    Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of inhibitors of platelet aggregation on the metabolism of platelet-activating factor (PAF) in washed rabbit platelets.
    O'Neill C; Ammit AJ; Korth R; Fleming S; Wells X
    Lipids; 1991 Dec; 26(12):1011-4. PubMed ID: 1726442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein-associated paf (LA-paf) was found in washed human platelets and monocyte/macrophage-like U937 cells.
    Korth R; Zimmermann K; Richter WO
    Chem Phys Lipids; 1994 Apr; 70(2):109-19. PubMed ID: 8033283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of nonsteroid antiinflammatory drugs on the specific binding of platelet activating factor to membrane preparations of rabbit platelets.
    Hwang SB; Cheah MJ; Lee CS; Shen TY
    Thromb Res; 1984 Jun; 34(6):519-31. PubMed ID: 6429890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.
    Pons F; Rossi AG; Norman KE; Williams TJ; Nourshargh S
    Br J Pharmacol; 1993 May; 109(1):234-42. PubMed ID: 8495241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists.
    Tokumura A; Yoshida J; Okasaka N; Fukuzawa K; Tsukatani H
    Thromb Res; 1987 Apr; 46(1):153-61. PubMed ID: 3590110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M; Tomomatsu N; Iwahisa Y; Yamaguchi S; Kawakami Y; Terasawa M
    Pharmacology; 1997 May; 54(5):261-70. PubMed ID: 9380772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High affinity specific binding sites for tritiated platelet-activating factor in canine platelet membranes: counterparts of platelet-activating factor receptors mediating platelet aggregation.
    Tahraoui L; Floch A; Mondot S; Cavero I
    Mol Pharmacol; 1988 Aug; 34(2):145-51. PubMed ID: 2842653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel class of platelet activating factor (PAF) antagonists. I. Synthesis and structure-activity studies on PAF-sulfonamide isosteres.
    Tsuri T; Haga N; Matsui T; Kamata S; Kakushi H; Uchida K
    Chem Pharm Bull (Tokyo); 1992 Jan; 40(1):75-84. PubMed ID: 1605805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro Anti-atherogenic Properties of N-Heterocyclic Carbene Aurate(I) Compounds.
    Sioriki E; Lordan R; Nahra F; van Hecke K; Zabetakis I; Nolan SP
    ChemMedChem; 2018 Dec; 13(23):2484-2487. PubMed ID: 30381909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and identification of hydroxyl-platelet-activating factor from natural sources.
    Tsoupras AB; Antonopoulou S; Baltas G; Samiotaki M; Panayotou G; Kotsifaki H; Mantzavinos Z; Demopoulos CA
    Life Sci; 2006 Oct; 79(19):1796-803. PubMed ID: 16860827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biological activity of acetylated sphingosylphosphorylcholine derivatives.
    Zanglis A; Lianos EA; Demopoulos CA
    Int J Biochem Cell Biol; 1996 Jan; 28(1):63-74. PubMed ID: 8624845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S; Mikashima H; Muramoto Y; Terasawa M; Setoguchi M; Tahara T
    Prostaglandins; 1990 Dec; 40(6):571-83. PubMed ID: 1965554
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K; Fray MJ; Parry MJ; Richardson K; Steele J
    J Med Chem; 1992 Aug; 35(17):3115-29. PubMed ID: 1507200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Platelet activating factor in surfactant-TA is inhibited by coexisting inhibitors.
    Koyama N
    Lung; 2003; 181(4):213-8. PubMed ID: 14692561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.